Our Copaxone® revenues outside the
United States were $180 million in the second quarter of 2017, a decrease of 3%, or an increase of 1% in local currency terms, compared to the second quarter of 2016. Over 75% of the total European Copaxone® prescriptions are now filled with the 40 mg/mL version.
Copaxone® accounted for approximately 18% of our revenues in the second quarter of 2017, and a significantly higher percentage contribution to our profits and cash flow from operations during this period.
Our U.S. Orange Book patents covering Copaxone® 20 mg/mL expired in May 2014.
Our patents on Copaxone® 20 mg/mL expired in May 2015 in most of the rest of the world. Accordingly, a key part of our strategy has been the introduction of Copaxone® 40 mg/mL, a higher dose of Copaxone® with a three times a week dosing regimen for patients with relapsing-remitting multiple sclerosis.
This formulation allows for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of MS.
Copaxone® 40 mg/mL was protected by five U.S. Orange Book patents that expire in 2030. All of the claims of three of those patents were declared to be unpatentable by the U.S. Patent Office in inter
partes review (IPR) proceedings, and we have appealed those decisions. A petition filed for an IPR against a fourth Orange Book patent was withdrawn on May 2, 2017. These four patents have also been challenged in paragraph IV
litigation in the United States. A trial was held in the United States District Court for the District of Delaware, and in January 2017 the court held that the asserted claims of these four patents were invalid. We have appealed this decision;
however, it is possible that certain competitors may receive FDA approval and launch competing products before either appeal is decided. A separate paragraph IV litigation in the United States regarding the fifth Orange Book patent, which was issued
in August 2016, has been dismissed with prejudice, but may nonetheless be revived pending the outcomes of appeals. We have also filed suit against multiple ANDA filers to assert a non-Orange Book process patent in various jurisdictions. Copaxone® 40 mg/mL is also protected by one European patent expiring in 2030. This patent is being challenged in the U.K. and Italy.
The market for MS treatments continues to change as a result of new and emerging therapies as well as a generic version of Copaxone® 20 mg/mL in the U.S., follow-on products in some European countries and potential competing purported generic versions of Copaxone® 40
mg/mL following the court ruling invalidating four Copaxone® 40 mg/mL patents in January 2017. In particular, the increasing number of oral treatments, such as Tecfidera®, Gilenya® and Aubagio® continue to present significant and increasing
competition. Copaxone® also continues to face competition from existing injectable products, such as the five beta-interferons Avonex®,
Plegridy®, Betaseron®, Extavia® and Rebif®, as well as from monoclonal antibodies such as Tysabri®, Lemtrada® and Zinbryta® and Ocrevus®.
Azilect® (rasagiline tablets) is indicated as initial monotherapy and as an adjunct to levodopa for the treatment of the signs and symptoms of Parkinsons disease, the second most common
neurodegenerative disorder. Generic competition for Azilect® in the United States commenced in 2017. Data exclusivity protection for
Azilect® in the EU expired in 2015. We continue to share marketing rights with Lundbeck in certain of our ROW markets. In June 2017,
Azilect® was submitted for approval in Japan, pursuant to an agreement with Takeda to market this product in Japan.
Our sales of Azilect® in the second quarter of 2017 were $34 million, a decrease of
69%, compared to the second quarter of 2016, mainly due to lower volumes following the introduction of generic competition in the United States and Europe.
Nuvigil® (armodafinil), the R-isomer of modafinil, is indicated for the
treatment of excessive sleepiness associated with narcolepsy and certain other disorders. Global sales of Nuvigil® in the second quarter of 2017 were $14 million, compared to $51 million in
the second quarter of 2016, due to generic competition that began in June 2016.
In April 2017, we launched AustedoTM (deutetrabenazine) in the United States, for the treatment of chorea associated with Huntington disease (HD). AustedoTM is
the first deuterated product approved by the FDA and the second product approved in HD. The product was previously granted Orphan Drug Designation by the FDA.
In May and June 2017, we announced that our phase 3 studies of fremanezumab for chronic migraine and episodic migraine met all primary
and secondary endpoints. Based on these results, we plan to submit biologics license applications to the FDA for fremanezumab later this year.
respiratory portfolio includes ProAir®, QVAR®, DuoResp Spiromax®, Qnasl®, Braltus ® and Cinqair®/Cinqaero®. Revenues from our specialty respiratory products in the second quarter of 2017 were $322 million, an increase of 3% compared to the second quarter of 2016, mainly due to the launches of
Braltus ® and Cinqair®/Cinqaero®, partially offset by lower
sales of ProAir® and QVAR®.